VITP tenant Vifor Pharma played a role in successful pivotal phase III study for PA21, a therapy aimed at controlling hyperphosphatemia in patients with chronic kidney disease on dialysis.

Hyperphosphatemia, the accumulation of phosphorus in the blood, is a common and serious condition in patients with CKD, particularly those requiring dialysis. While all dialysis patients are treated with phosphate binders, less than 50% achieve and maintain their target serum phosphorus levels. Hyperphosphatemia is a risk factor for CKD complications such as cardiovascular disease, secondary hyperparathyroidism and renal bone disease.

Victoria BC’s Aspreva International Ltd,  a division of Vifor Pharma –  is part of the Swiss Galencia group, and is an speciality pharmaceutical company focused on iron deficiency anaemia. The Swiss healthcare products supplier and drugmaker Galenica (GALN.S) acquired Victoria’s Aspreva Pharmaceuticals (which started its life as a Vancouver Island Tech Park tenant) in 2007 for more than $900 million.

Aspreva Pharmaceuticals achieved tremendous success by specializing in the research and commercialization of new therapeutic indications for already registered drugs and while working closely with Swiss drugmaker Roche.

Official Press Release available here.